Marksans Pharma Reports 20.2% Operating Revenue Growth in FY 2024-25

Marksans Pharma Ltd, a globally-trusted, customer-centric pharmaceutical company, has reported a 20.2% growth in operating revenue for the Financial Year 2024-25. The company specializes in developing and manufacturing both over-the-counter (OTC) and prescription (Rx) drugs, aligning their offerings with the evolving needs of patients and healthcare providers across the world. Marksans Pharma's strength lies in its agile, integrated business model that combines advanced R&D capabilities with streamlined manufacturing processes and engaging marketing operations. The company's unwavering focus on Quality Control (QC) and Quality Assurance (QA) has enabled it to exceed industry benchmarks and build enduring partnerships in over 50 countries.